0.78
-0.0011(-0.14%)
Currency In USD
| Previous Close | 0.78 |
| Open | 0.81 |
| Day High | 0.82 |
| Day Low | 0.74 |
| 52-Week High | 2.75 |
| 52-Week Low | 0.55 |
| Volume | 103,989 |
| Average Volume | 153,503 |
| Market Cap | 69.96M |
| PE | -1.7 |
| EPS | -0.46 |
| Moving Average 50 Days | 0.79 |
| Moving Average 200 Days | 1.49 |
| Change | -0 |
If you invested $1000 in Context Therapeutics Inc. (CNTX) since IPO date, it would be worth $152.92 as of May 12, 2025 at a share price of $0.78. Whereas If you bought $1000 worth of Context Therapeutics Inc. (CNTX) shares 3 years ago, it would be worth $565.14 as of May 12, 2025 at a share price of $0.78.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Context Therapeutics Reports First Quarter 2025 Operating and Financial Results
GlobeNewswire Inc.
May 07, 2025 8:09 PM GMT
CTIM-76 and CT-95 in Phase 1 Clinical Trials Cash and cash equivalents of $89.4 million as of March 31, 2025 Company expects its cash and cash equivalents will continue to fund operations into 2027 PHILADELPHIA, May 07, 2025 (GLOBE NEWSWIRE) -- Con
Context Therapeutics Announces Chief Medical Officer Transition
GlobeNewswire Inc.
May 05, 2025 8:05 PM GMT
Board Member Dr. Karen Smith to serve as Interim Chief Medical OfficerPHILADELPHIA, May 05, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell enga
Context Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 2025 AACR Annual Meeting
GlobeNewswire Inc.
Apr 30, 2025 11:30 AM GMT
Preclinical data demonstrates unique binding location of CT-95 on mesothelin and avoidance of binding to shed mesothelin Data supports ongoing Phase 1 clinical trial for CT-95 PHILADELPHIA, April 30, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics